Human liver progenitors

• US 20050148072A1
• Filed: 09/21/2004
• Published: 07/07/2005
• Est. Priority Date: 01/19/1999
• Status: Abandoned Application

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Kubota, Hiroshi, Reid, Lola M., Moss, Nicholas
• Application Number:
  US10/944,919
• Publication Number:
  US 20050148072A1
• Time in Patent Office: Days
• US Class Current: 435/370
• CPC Class Codes: A61K 2039/55594 from bacteria
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C12N 2500/20 Transition metals
• CPC Class Codes: C12N 2500/22 Zinc; Zn chelators
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/36 Lipids
• CPC Class Codes: C12N 2503/02 Drug screening
• CPC Class Codes: C12N 5/0672 Stem cells; Progenitor cells; Precursor cells; Oval cells

Abstract

Methods of isolating and cryopreserving progenitors from human liver are disclosed which include processing human liver tissue to provide a substantially single cell suspension comprising progenitors and non-progenitors of one or more cell lineages found in human liver; subjecting the suspension to a debulking step, which reduces substantially the number of non-progenitors in the suspension, and which provides a debulked suspension enriched in progenitors exhibiting one or more markers associated with at least one of the one or more cell lineages; and selecting from said debulked suspension those cells, which themselves, their progeny, or more mature forms thereof express one or more markers associated with at least one of the one or more cell lineages. Among these markers are CD14, CD34, CD38, CD45, and ICAM. Hepatic progenitors are characterized as being 6-15μ in diameter, diploid, glycophorin A⁻, CD45⁻, AFP⁺⁺⁺, ALB⁺, ICAM⁺, and with subpopulations varying in expression of CD14⁺. CD34⁺⁺, CD38⁺⁺, CD117⁺. These progenitor subpopulations have characteristics expected for cells that are particularly useful in liver cell and gene therapies and for establishing bioartificial organs.

Claims

49. A method of preparing a composition comprising a mixture of cells derived from human liver tissue, which mixture comprises an enriched population of human liver progenitors, the method comprising:

(a) providing a cell suspension of human liver tissue comprising a mixture of cells of varying sizes, including immature cells and mature cells; and

(b) debulking the suspension based on cell size, buoyant density, or a combination thereof to remove mature cells, while retaining immature cells,

to provide a mixture of cells comprised of an enriched population of human liver progenitors.

50. The method of claim 49, in which the liver tissue is obtained from a fetus, a neonate, an infant, a child, a juvenile, or an adult.

51. The method of claim 49 in which the immature cells have a diameter less than about 15 microns.

52. The method of claim 49 in which the enriched population comprises human diploid liver cells.

53. The method of claim 49 in which the liver progenitors are hepatic progenitors, hemopoietic progenitors, mesenchymal progenitors, or mixtures thereof.

54. The method of claim 49 in which the alpha-fetoprotein is full-length alpha-fetoprotein.

55. The method of claim 49 in which the debulking step comprises centrifugal elutriation, density gradient centrifugation, countercurrent fluid flow, continuous-flow centrifugation, zonal centrifugation, or combinations thereof.

56. The method of claim 49 which further comprises selective lysis of the mature cells.

65. The method of claim 49 in which the progenitors have a diameter between 5 and 15 microns.

66. The method of claim 65 in which the progenitors have a diameter between 8 and 9.4 microns.

67. The method of claim 49 which further comprises selecting those cells which their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both.

68. The method of claim 67 in which the selection step comprises panning, affinity chromatography, tagging with fluorescent labels, use of magnetic beads, or combinations thereof.

57. A method of preparing a composition comprising an enriched population of human hepatic progenitors comprising:

(a) providing a cell suspension of human liver tissue,

(b) debulking the suspension based on cell size, buoyant density, or a combination thereof to remove mature cells, and

(c) subjecting the debulked suspension to a positive or negative immunoselection, such that a mixture of cells is provided, which mixture of cells is comprised of an enriched population of human hepatic progenitors, which human hepatic progenitors themselves, their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both.

58. The method of claim 57 in which the immunoselection comprises selecting cells that express markers associated with hemopoietic cells, cells that express markers associated with hepatic cells, cells that express markers associated with mesenchymal cells, or combinations thereof.

59. The method of claim 57 in which the immunoselection comprises selecting from the suspension those cells, which themselves, their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both.

60. The method of claim 59 which further comprises selecting those cells which themselves, their progeny, or more mature forms thereof produce full length alpha-fetoprotein mRNA.

61. The method of claim 57 in which the immunoselection comprises selecting from the suspension those cells that express an adult liver cell-specific marker.

62. The method of claim 57 in which the immunoselection comprises selecting those cells, which themselves, their progeny, or more mature forms thereof express CD14, CD34, CD38, ICAM, CD45, CD117, glycophorin A, connexin 32, osteopontin, bone sialoprotein, collagen I, collagen II, collagen III, collagen IV, or combinations thereof.

63. The method of claim 57 which the immunoselection comprises selecting those cells, which themselves, their progeny, or more mature forms thereof further express alpha-fetoprotein-like immunoreactivity, albumin-like immunoreactivity, or a combination thereof.

64. A cell culture comprising an enriched population of human hepatic pluripotent progenitors, their progeny, or more mature forms thereof, which exhibit one or more markers indicative of expression of full-length alpha-fetoprotein, full-length albumin, or both, an extracellular matrix component, and a culture medium.